Vascular Biogenics Insiders
VBLTDelisted Stock | USD 0.28 0.01 3.45% |
Vascular Biogenics employs about 7 people. The company is managed by 9 executives with a total tenure of roughly 44 years, averaging almost 4.0 years of service per executive, having 0.78 employees per reported executive. Breaking down Vascular Biogenics' management performance can provide insight into the firm performance.
Yael Cohen President Vice President - Clinical Development |
Eyal Breitbart President Vice President Research |
Vascular |
Vascular Biogenics Management Team Effectiveness
The company has return on total asset (ROA) of (0.2912) % which means that it has lost $0.2912 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5952) %, meaning that it created substantial loss on money invested by shareholders. Vascular Biogenics' management efficiency ratios could be used to measure how well Vascular Biogenics manages its routine affairs as well as how well it operates its assets and liabilities.Vascular Biogenics Workforce Comparison
Vascular Biogenics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 744. Vascular Biogenics maintains roughly 7.0 in number of employees contributing less than 1% to equities under Health Care industry.
Vascular Biogenics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Vascular Biogenics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Vascular Biogenics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Vascular Biogenics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Samuel Backenroth over a year ago Exercise or conversion by Samuel Backenroth of 525000 shares of Vascular Biogenics subject to Rule 16b-3 |
Vascular Biogenics Notable Stakeholders
A Vascular Biogenics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Vascular Biogenics often face trade-offs trying to please all of them. Vascular Biogenics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Vascular Biogenics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Yael Cohen | Vice President - Clinical Development | Profile | |
Eyal Breitbart | Vice President Research | Profile | |
Naamit Sher | VP of Devel. and Regulatory | Profile | |
Samuel Backenroth | Chief Officer | Profile | |
Erez MBA | Sr Operations | Profile | |
Deborah Scott | Managing Communications | Profile | |
Pr MD | CEO Director | Profile | |
Advocate Horn | G Counsel | Profile | |
Tami MD | VP Devel | Profile |
About Vascular Biogenics Management Performance
The success or failure of an entity such as Vascular Biogenics often depends on how effective the management is. Vascular Biogenics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Vascular management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Vascular management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modiin, Israel. Vascular Biogen operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 41 people.
Please note, the imprecision that can be found in Vascular Biogenics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Vascular Biogenics. Check Vascular Biogenics' Beneish M Score to see the likelihood of Vascular Biogenics' management manipulating its earnings.
Vascular Biogenics Workforce Analysis
Traditionally, organizations such as Vascular Biogenics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Vascular Biogenics within its industry.Vascular Biogenics Manpower Efficiency
Return on Vascular Biogenics Manpower
Revenue Per Employee | 94K | |
Revenue Per Executive | 73.1K | |
Net Loss Per Employee | 4.6M | |
Net Loss Per Executive | 3.6M | |
Working Capital Per Employee | 2.2M | |
Working Capital Per Executive | 1.7M |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Other Consideration for investing in Vascular Stock
If you are still planning to invest in Vascular Biogenics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Vascular Biogenics' history and understand the potential risks before investing.
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |